Survival Analysis of Triple Negative Breast Cancer Patients Treated with Anthracycline based Chemotherapy in Central Part of India

Introduction: TNBC (triple negative breast cancer) is more common in younger and premenopausal women. TNBC are biologically aggressive tumors that have not responded well to hormonal or targeted therapy, despite some evidence that they do respond well to chemotherapy. The purpose of this study was to evaluate the efficacy of anthracycline-based adjuvant chemotherapy in triple negative breast cancer.

Objective: To assess the survival outcome in triple negative breast cancer patients after treatment with Anthracycline based chemotherapy.

Materials and Methods: This was a retrospective study of 100 post-operative patients with histopathologically proven ductal Carcinoma Breast who presented to a tertiary care centre between January 2016 and March 2017. According to immunohistochemistry and the fluorescence in situ hybridization technique, all patients were triple negative. Six cycles of Anthracycine-based combination adjuvant chemotherapy were planned for the patients. SPSS 20 was used to analyse the data, and a survival analysis was performed.

Results: This study included 100 patients in total. 18 patients (18%) defaulted after chemotherapy, 29 patients (29%) were lost during subsequent follow-ups, 49 patients (49%) had disease free survival (DFS), and 4 patients (4%) survived with bone metastasis. The median survival time was 18 months, the disease-free survival time was 7.8 months, and the three-year overall survival (OS) time was 18.6 months.

Conclusions: Because of its poor prognosis and limited treatment options, TNBC poses a challenge for both patients and clinicians. Adjuvant Anthracycline-based combination chemotherapy for TNBC predicts better long-term outcomes.